Loading

pharmacist Information

All information about pharmacist, pharmacist Latest News

CMS looking into whether to pay for Provenge

Dendreon shares fell $5.64, or 17.5 percent, in after-hours trading last night

Shire Purchases Strategic Site in Massachusetts

Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced its purchase of the Lexington Technology Park campus in Lexington, Massachusetts.

Original Source of Shire Purchases Strategic Site in Massachusetts

Manhattan Research Releases Latest Study Focused on How Nurses Use the Internet and Technology

Pharmaceutical and healthcare market research company Manhattan Research releases Taking the Pulse® Nurses v10.0, the latest iteration of its study focused on how nurses use digital resources, handheld devices, and other technologies in the professional setting.

Original Source of Manhattan Research Releases Latest Study Focused on How Nurses Use the…

AstraZeneca wins key Crestor patent fight

AstraZeneca

Key drugs for AZ, Pfizer get generic rivals

Two big drugs got generic competition in the U.S. this week. First, there’s AstraZeneca’s ( NYSE: AZN )

Avandia decision a bellwether for Obama FDA

Obviously, the fate of GlaxoSmithKline’s ( NYSE: GSK )

Celgene moves into solid tumors with Abraxis buy

When Celgene

Bayer backs off Teva’s premature Yaz copy

Bayer withdrew its patent lawsuit against Teva Pharmaceutical Industries for allegedly infringing Bayer’s Yaz contraceptive with its Gianvi generic, according to court documents. Report

Original Source of Bayer backs off Teva’s premature Yaz copy

Abbott targets sale of Solvay flu-vax unit

Abbott Laboratories doesn’t plan to hold onto Solvay’s flu vaccine business. The company started marketing the unit last week, sources tell the Wall Street Journal , by sending out materials to several large healthcare companies. The business could fetch some €500 million, or $619 million. Abbott bought Solvay’s drugs…

Journal questions independence of key Crestor trial

Did financial ties to drugmaker AstraZeneca ( NYSE: AZN ) prejudice researchers in the pivotal trial that showed its cholesterol fighter Crestor prevented heart disease? An article in the new Archives of Internal Medicine raises that question, pointing out that nine of the 14 researchers who ran the Jupiter…